Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

609 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Retrospective analysis of results of p(65)+Be neutron therapy for treatment of prostate adenocarcinoma at the cyclotron of Louvain-la-Leuve. Part II: Side effects and their influence on quality of life measured with QLQ-C30 of EORTC.
Scalliet PG, Remouchamps V, Curran D, Ledent G, Wambersie A, Richard F, van Cangh P. Scalliet PG, et al. Among authors: curran d. Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1549-61. doi: 10.1016/j.ijrobp.2003.09.001. Int J Radiat Oncol Biol Phys. 2004. PMID: 15050336 Review.
A retrospective analysis of the results of p(65) + Be neutrontherapy for the treatment of prostate adenocarcinoma at the cyclotron of Louvain-la-Neuve. Part I: Survival and progression-free survival.
Scalliet PG, Remouchamps V, Lhoas F, Van Glabbeke M, Curran D, Ledent T, Wambersie A, Richard F, Van Cangh P. Scalliet PG, et al. Among authors: curran d. Cancer Radiother. 2001 Jun;5(3):262-72. doi: 10.1016/s1278-3218(01)00102-0. Cancer Radiother. 2001. PMID: 11446080
Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist.
Kramer JA, Curran D, Piccart M, de Haes JC, Bruning PF, Klijn JG, Bontenbal M, van Pottelsberghe C, Groenvold M, Paridaens R. Kramer JA, et al. Among authors: curran d. Eur J Cancer. 2000 Aug;36(12):1488-97. doi: 10.1016/s0959-8049(00)00134-9. Eur J Cancer. 2000. PMID: 10930796 Clinical Trial.
A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group.
Bjordal K, de Graeff A, Fayers PM, Hammerlid E, van Pottelsberghe C, Curran D, Ahlner-Elmqvist M, Maher EJ, Meyza JW, Brédart A, Söderholm AL, Arraras JJ, Feine JS, Abendstein H, Morton RP, Pignon T, Huguenin P, Bottomly A, Kaasa S. Bjordal K, et al. Among authors: curran d. Eur J Cancer. 2000 Sep;36(14):1796-807. doi: 10.1016/s0959-8049(00)00186-6. Eur J Cancer. 2000. PMID: 10974628
Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer.
Rosendahl I, Kiebert GM, Curran D, Cole BF, Weeks JC, Denis LJ, Hall RR. Rosendahl I, et al. Among authors: curran d. Prostate. 1999 Feb 1;38(2):100-9. doi: 10.1002/(sici)1097-0045(19990201)38:2<100::aid-pros3>3.0.co;2-x. Prostate. 1999. PMID: 9973095 Clinical Trial.
609 results